Study of pozelimab with cemdisiran for geographic atrophy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have geographic atrophy (a type of advanced dry age-related macular degeneration) in at least one eye
- The area of damage in your study eye is between 2.5 and 17.5 square millimeters
- Your vision in the study eye is 20/80 or better (you can read some letters on an eye chart)
- You are willing to get meningococcal and pneumococcal vaccines before starting the study
- You have not had any eye injections for any reason in the last 6 months
- You do not have wet macular degeneration or other eye conditions that could affect your vision
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This trial tests whether a monthly injection of pozelimab into the eye can slow the growth of geographic atrophy (a late form of dry age-related macular degeneration). It may help people who have significant vision loss from this condition.
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Hear when a new Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.